Giant Biogene Holding (GBHC.F) Stock Overview

An investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. More details

GBHC.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	1/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 44.2% below our estimate of its fair value

Earnings are forecast to grow 11.77% per year

Risk Analysis

High level of non-cash earnings

Shares are highly illiquid

Dividend of 4.51% is not well covered by free cash flows

GBHC.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Giant Biogene Holding Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Giant Biogene Holding
Historical stock prices
Current Share Price	HK$4.22
52 Week High	HK$4.22
52 Week Low	HK$4.22
Beta	0.72
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	GBHC.F	US Personal Products	US Market
7D	0%	-2.1%	1.4%
1Y	n/a	-16.2%	25.7%

Return vs Industry: Insufficient data to determine how GBHC.F performed against the US Personal Products industry.

Return vs Market: Insufficient data to determine how GBHC.F performed against the US Market.

Price Volatility

Is GBHC.F's price volatile compared to industry and market?
GBHC.F volatility
GBHC.F Average Weekly Movement	n/a
Personal Products Industry Average Movement	8.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GBHC.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GBHC.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	2,201	Jianya Yan	www.xajuzi.com

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products.

Giant Biogene Holding Co., Ltd. Fundamentals Summary

How do Giant Biogene Holding's earnings and revenue compare to its market cap?
GBHC.F fundamental statistics
Market cap	US$4.20b
Earnings (TTM)	US$281.93m
Revenue (TTM)	US$812.50m

14.9x

P/E Ratio

5.2x

P/S Ratio

Is GBHC.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GBHC.F income statement (TTM)
Revenue	CN¥5.52b
Cost of Revenue	CN¥1.09b
Gross Profit	CN¥4.43b
Other Expenses	CN¥2.52b
Earnings	CN¥1.91b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.80
Gross Margin	80.34%
Net Profit Margin	34.70%
Debt/Equity Ratio	0%

How did GBHC.F perform over the long term?

See historical performance and comparison

Dividends

4.5%

Current Dividend Yield

29%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/13 02:51
End of Day Share Price	2026/02/13 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Giant Biogene Holding Co., Ltd. is covered by 21 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Melinda Hu	Bernstein
Ethan Cui	BofA Global Research
Zhuonan Xu	China International Capital Corporation Limited

Giant Biogene Holding Co., Ltd.OTCPK:GBHC.F Stock Report